Krüppel‐like factor 4 promotes c‐Met amplification‐mediated gefitinib resistance in non‐small‐cell lung cancer
Open Access
- 6 April 2018
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 109 (6) , 1775-1786
Abstract
Gefitinib has been widely used in the first‐line treatment of advanced EGFR‐mutated non‐small‐cell lung cancer (NSCLC). However, many NSCLC patients will acquire resistance to gefitinib after 9‐14 months of treatment. This study revealed that Krüppel‐like factor 4 (KLF4) contributes to the formation of gefitinib resistance in c‐Met‐overexpressing NSCLC cells. We observed that KLF4 was overexpressed in c‐Met‐overexpressing NSCLC cells and tissues. Knockdown of KLF4 increased tumorigenic properties in gefitinib‐resistant NSCLC cell lines without c‐Met overexpression, but it reduced tumorigenic properties and increased gefitinib sensitivity in gefitinib‐resistant NSCLC cells with c‐Met overexpression, whereas overexpression of KLF4 reduced gefitinib sensitivity in gefitinib‐sensitive NSCLC cells. Furthermore, Western blot analysis revealed that KLF4 contributed to the formation of gefitinib resistance in c‐Met‐overexpressing NSCLC cells by inhibiting the expression of apoptosis‐related proteins under gefitinib treatment and activating the c‐Met/Akt signaling pathway by decreasing the inhibition of β‐catenin on phosphorylation of c‐Met to prevent blockade by gefitinib. In summary, this study's results suggest that KLF4 is a promising candidate molecular target for both prevention and therapy of NSCLC with c‐Met overexpression.Keywords
Funding Information
- National Natural Science Foundation of China (81472774)
This publication has 45 references indexed in Scilit:
- Krüppel-like factor 4 (KLF4): What we currently knowGene, 2017
- MiR-145 negatively regulates Warburg effect by silencing KLF4 and PTBP1 in bladder cancer cellsOncotarget, 2017
- Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitroOncotarget, 2017
- KLF4 regulates adult lung tumor-initiating cells and represses K-Ras-mediated lung cancerCell Death & Differentiation, 2015
- Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitorsRespiratory Investigation, 2014
- Klf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8)PLOS ONE, 2013
- Deficiency of the Kruppel-like factor KLF4 correlates with increased cell proliferation and enhanced skin tumorigenesisCarcinogenesis, 2012
- KLF4 Interacts with β-Catenin/TCF4 and Blocks p300/CBP Recruitment by β-CateninMolecular and Cellular Biology, 2010
- Loss of Krüppel-Like Factor 4 Expression Contributes to Sp1 Overexpression and Human Gastric Cancer Development and ProgressionClinical Cancer Research, 2006
- KLF4, p21 and context-dependent opposing forces in cancerNature Reviews Cancer, 2005